Key Market Overview:
Meningococcal Vaccines Market was worth USD 3.11 Billion in 2021, and the market is estimated to witness a growth of USD 5.85 Billion by 2030 at a CAGR of 7.28% during the forecast period (2022-2030).
Meningococcal disease is a serious bacterial infection that causes meningitis (inflammation of the lining of the brain and spinal cord) and sepsis (blood infection) and further leads to permanent damage or even death. However, several types of meningococcal vaccines exist to offer protection against different types of meningococcal bacteria. Moreover, the most common types of meningococcal vaccines are conjugate meningococcal vaccines and polysaccharide meningococcal vaccines. Certain people are at increased risk of getting meningococcal disease, including infants, adolescents, and young adults between 16-23 years of age, and microbiologists working with isolates of N. meningitides. For all the above-listed reasons safe and effective vaccines are available worldwide for the prevention of invasive meningococcal disease along with the presence of primary care immunization service providers for facilitating the widespread uptake of meningococcal vaccines. Furthermore, MenACWY vaccine is also provided for children aged 12 months and adolescents under the National Immunization Program.
According to the US Food and Drug Administration (FDA), individuals of age 18 or above are administered PREVNAR 20, Pfizer’s Pneumococcal 20-valent Conjugate vaccine to help prevent invasive meningococcal disease. Additionally, the World Health Organization recommends that the MenACWY vaccines should be administered to all children and adolescents, typically at 11-12 years of age, with a booster dose around 16 years of age.
Geographically, North America is expected to be the fastest-growing market during the forecast period. Factors such as the high adoption rate of meningococcal vaccines in the U.S. and Canada, increasing government initiatives to promote vaccination, and the growing awareness about the meningococcal disease among people are expected to drive the growth of the market in the region. In addition to this, North American Vaccine Inc (NAVI) has launched a conjugate polysaccharide vaccine for the prevention of meningitis caused by group C meningococcal bacteria which is also anticipated to bolster market growth.
- The growth of the meningococcal vaccine market is being propelled by the availability of a diverse range of vaccines for individuals of varying ages. This provides increased options for individuals to protect themselves from serious and life-threatening consequences of meningococcal disease, thereby driving demand for the product.
- The expansion of the meningococcal vaccine market is being fueled by the growing global awareness of the meningococcal disease and the increased efforts by governments to promote and implement vaccination programs. This heightened focus on preventative measures against the disease is driving demand and contributing to the growth of the meningococcal vaccine market.
- The high cost of meningococcal vaccines presents a restraint to patients, limiting their accessibility and hindering the growth of the market. This economic barrier is a significant factor that restricts the expansion of the meningococcal vaccine market.
- The risks associated with the vaccine reaction such as redness or soreness where the shot is given along with the pain, headache, or tiredness in case of meningococcal ACWY vaccination is expected to hamper the growth of the market.
The implementation of a well-organized and transparent process for incorporating the MenACV vaccine into national immunization programs is poised to create significant growth opportunities for the market. Furthermore, ensuring the availability of a rolling buffer stock to address unexpected shipment delays and changes in demand is also expected to drive market growth in the future. Proactively establishing a buffer stock before launching the vaccine will further contribute to the growth potential of the market.
Meningococcal Vaccines Report Coverage:
|Report Attributes||Report Details|
|Market Size in 2030 (USD Billion)||5.85 Billion|
|By Disease type||Meningitis, Septicemia, Pneumonia, Meningococcemia, and Others.|
|By Vaccine Type||Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and Others|
|By Age Group||Infants, Children, and Adults.|
|By Brand Name||Menactra, Menveo, Nimenrix, Trumenba, Bexsero, and Others|
|By Distribution Channel||Pharmacies (Retail and Online), Community Clinics, Public Health Departments, and Others.|
|By Geography||North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa|
|Key Players||GlaxoSmithKline (GSK), Pfizer, Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India, Bharat Biotech, Bio Farma, Panacea Biotec Ltd, and Biomed Pvt. Ltd.|
By Disease Type:
Depending on the disease type, the market is separated into meningitis, septicemia, pneumonia, meningococcemia, and others. Meningitis is considered to be the dominant segment as this is the most serious and life-threatening form of meningococcal disease. Moreover, meningitis disease results in severe complications such as brain damage, amputations, and death. Therefore, meningitis is likely to be a significant contributor to the overall market share of the meningococcal vaccines market.
Moreover, septicemia and pneumonia are anticipated to grow at the fastest CAGR over the forecast period as both are serious and life-threatening forms of meningococcal disease and are also common indications for meningococcal vaccination.
By Vaccine Type:
Based on the vaccine type, the market is divided into polysaccharide vaccines, conjugate vaccines, combination vaccines, and others. Conjugate vaccines is the dominant segment and contribute to the largest share of the market as this vaccine is widely adopted by most countries in the vaccination schedule. Moreover, conjugate vaccines are more effective in young children to help the immune system recognize and remember the bacteria. Additionally, conjugate vaccines are available for serogroups A, C, W, and Y and are administered in a series of doses to children, adolescents, and young adults.
By Age Group:
The age group segment is bifurcated into infants, children, and adults. The adult age group is the dominant segment and contributes to the largest share of the meningococcal vaccines market. As adolescents are at an increased risk of the isease due to increased social interactions and close living quarters, and the changes in their immune system during puberty. Adolescents or young adults are typically given a booster dose of the meningococcal conjugate vaccine at age 11-12 years and again at age 16 years.
Certain infants with complex congenital heart disease have asplenia, and infants with sickle cell disease often are identified at increased risk due to serogroups C or Y meningococcal disease outbreaks for which vaccination is recommended. Furthermore, infants and young children are also a significant segment of the market and are anticipated to grow at a steady pace during the forecast period.
By Brand Name:
The brand name segment is categorized into Menveo, Menactra, Trumenba, Nimenrix, Bexsero, and others. Bexsero has dominated the market and contributed to the largest share of market revenue in 2021. As Bexsero is widely used in more than 40 countries, such as New Zealand, Uruguay, Australia, Israel, Argentina, Chile, Turkey, and Europe, and is licensed for individuals aged 2 months & above. This is the key factor driving the segment growth. Moreover, Bexsero is a vaccine that protects individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitides (group B). In addition, a single booster dose produces a stronger immune response in children.
By Distribution Channel:
The distribution channel is segmented into pharmacies, community clinics, public health departments, and others. The public health department holds the largest share of the meningococcal market. As the public health department is responsible for providing vaccinations to the general public, including school-aged children, as well as individuals who have a higher risk of contracting meningococcal disease. Moreover, the public health departments also work in collaboration with other organizations such as hospitals, doctors’ offices, and community clinics to provide vaccinations.
Furthermore, pharmacies and community clinics are anticipated to witness the fastest CAGR over the forecast period. As pharmacies and community clinics play an important role in distributing meningococcal vaccines and providing access to vaccines to people who face difficulty in visiting public health departments. Pharmacies are also subdivided into retail and online.
The regional segment includes Asia Pacific, Europe, North America, the Middle East & Africa, and Latin America. Asia Pacific region is dominating and contributes to the largest share of the market. Factors such as increasing population and improving healthcare infrastructure, in the region are driving the market growth in Asia Pacificarticularly, China which is the largest consumer, accounting for 34% of global demand, primarily for polysaccharide vaccines. Moreover, the presence of major pharmaceutical companies and manufacturers of meningococcal vaccines in the Asia Pacific contributes to a significant market share.
Moreover, the U.S. is also anticipated to grow at the fastest CAGR over the forecast period as North America comprises of well-established national vaccination programs that provide routine vaccination against meningococcal disease. A large number of travelers in the country are the factors that increase the risk of spread of the disease and hence, is expected to drive the growth of the market.
Meningococcal Vaccines Market Competitive Landscape:
The meningococcal vaccines market is highly competitive, with several key players offering various types of vaccines. These companies compete on factors such as price, efficacy, safety, and accessibility of their vaccines, as well as their marketing and distribution strategies. In addition, several emerging players are focusing on developing new and innovative meningococcal vaccines, which is likely to further increase the level of competition in the market in the coming years. Key companies include-
- GlaxoSmithKline (GSK)
- Merck & Co., Inc.
- Sanofi Pasteur
- Serum Institute of India
- Bharat Biotech
- Bio Farma
- Panacea Biotec Ltd
- Biomed Pvt. Ltd
- In 2021, Pfizer announced that it has received the European Medicines Agency’s approval for its Trumenba vaccine for use in adolescents and adults aged 10 to 25 years, for the prevention of invasive meningococcal disease caused by serogroup B.
- In 2020, GSK announced the launch of Menveo Quadrivalent in Canada, which is the first and only quadrivalent meningococcal conjugate vaccine for active immunization against meningococcal disease caused by serogroups A, C, W-135, and Y.
Table of Content
To check our Table of Contents, please mail us at: [email protected]
Research MethodologyThe Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.
Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.